DAE HWA Pharmaceutical Co., Ltd. announces an Equity Buyback for 360,000 shares.
August 06, 2019 at 03:19 am EDT
Share
DAE HWA Pharmaceutical Co., Ltd. (KOSDAQ:A067080) announces a share repurchase program. Under the program, the company will repurchase up to 360,000 shares pursuant to a trust contract with Samsung Securities Co., Ltd. The purpose of the program is to improve shareholder value through stabilization of stock price. The program will expire on November 6, 2019. As of August 5, 2019, the company had 540,627 shares in treasury within scope available for dividend and had 0 shares in treasury through other repurchase.
DAE HWA PHARM CO.,LTD. is a Korea-based company engaged in the manufacture of pharmaceuticals. The Companyâs products include skeletal muscle relaxants, gastro-intestinal drugs, corticosteroids, antihistamines, cardiovascular drugs, drugs for liver diseases, vitamins, tonics, antibiotics, injections, topical drugs, anti-inflammatory enzymes, analgesics, antipyretics, plaster, cough suppressants, expectorants and mucolytics, drugs for hemorrhoid disease and other prescription drugs, as well as over-the-counter (OTC) drugs. The Company distributes its products within domestic market and to overseas markets. On August 22, 2013, it acquired a certain shares of a Korea-based company, which is mainly engaged in the manufacture of medicine raw materials and development of medical devices. After the transaction, the Company held a 100% stake of the Korea-based company.
DAE HWA PHARMACEUTICAL CO., LTD. 
